阿托伐他汀对肾小球硬化大鼠TGF-β_1的影响

The effect and mechanism of atrovastatin on TGF-β_1 of progressive glomerulassclerosis in rats

目的探讨阿托伐他汀对肾小球硬化大鼠TGF-β1的影响。方法36只健康Wistar大鼠随机分为对照组、模型组和治疗组。模型组与治疗组行5/6肾脏切除制备肾病模型,治疗组给予阿托伐他汀4 mg/(kg.d),饲养4周和9周,观察血脂、尿蛋白和肾脏病理改变。结果治疗组第4周和第9周尿蛋白、肾脏病理积分明显低于模型组(P<0.05)。肾组织损伤也明显减轻,两组肾小球硬化指数差异有统计意义(P<0.05)。逆转录—聚合酶联反应(RT-PCR)半定量分析显示治疗组转化生长因子-β1(TGF-β1)及其mRNA表达减少。血清胆固醇(CHO)、高密度脂蛋白(HDL)及甘油三酯(TG)在治疗前后差异无统计学意义(P>0.05)。结论阿托伐他汀可减轻肾小球硬化,其机制之一为减少细胞外基质TGF-β1在肾脏的表达。

Objective： to determine the effect and mechanism of atrovastatin on TGF-β1 of progressive glomerulassclerosis in rats. Methods： Thirty -six healthy Wistar rats were equally divided into 3 groups randomly： normal control, progressive glomerulassclerosis and glomerulassclerosis with atrovastatin4mg/（ kg·d） for 4 weeks or 9 weeks. Urinary protein excretion and serum lipid were assayed, renal glomeruloselerosis index and the expression of transforming growth factor-β1 （ TGF-β1 ） were observed in the 5/6 nephrectomized rats. Results： The renal damage was less marked in atrovastatin-treated rats. RTPCR revealed that the expression of TGF-β1 was also sharply lower in treatment group than that in glomerulosclerosis group. Howewer, serum total cholesterol and trigtycerldes were not changed significantly in all the rats （P 〈 0.0） Conclusion： Our findings indicate that atrovastatin can lesson glomerular injury and one of its mechanism is the decreasing in the expression of TGF-β1 in renal tissue.